Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

BACKGROUND: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). The aim...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Lee, Sae Hwan, Song, Il Han, Noh, Ran, Kang, Ha Yan, Kim, Suk Bae, Ko, Soon Young, Lee, Eoum Seok, Kim, Seok Hyun, Lee, Byung Seok, Kim, An Na, Chae, Hee Bok, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Lee, Jae Dong, Lee, Heon Young
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4403976/
https://ncbi.nlm.nih.gov/pubmed/25885683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1273-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items